Chugai Pharmaceutical Co., Ltd. (CUP0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chugai Pharmaceutical Co., Ltd. (CUP0) has a cash flow conversion efficiency ratio of 0.040x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€70.65 Billion) by net assets (€1.75 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chugai Pharmaceutical Co., Ltd. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Chugai Pharmaceutical Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Chugai Pharmaceutical Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chugai Pharmaceutical Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Schlumberger Limited
SA:SLBG34
|
0.249x |
|
Synopsys Inc
NASDAQ:SNPS
|
0.028x |
|
Ecolab Inc
NYSE:ECL
|
0.081x |
|
Royal Caribbean Cruises Ltd
NYSE:RCL
|
0.143x |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
0.177x |
|
INVESTOR B (FRIA) O.N.
F:IVSD
|
N/A |
|
Investor AB ser. B
ST:INVE-B
|
0.005x |
|
Vinci S.A.
PA:DG
|
0.382x |
Annual Cash Flow Conversion Efficiency for Chugai Pharmaceutical Co., Ltd. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Chugai Pharmaceutical Co., Ltd. from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €2.03 Trillion | €386.28 Billion | 0.191x | -18.99% |
| 2024-12-31 | €1.90 Trillion | €447.60 Billion | 0.235x | -6.65% |
| 2023-12-31 | €1.63 Trillion | €409.93 Billion | 0.252x | +47.46% |
| 2022-12-31 | €1.42 Trillion | €243.58 Billion | 0.171x | -27.35% |
| 2021-12-31 | €1.19 Trillion | €279.63 Billion | 0.235x | -- |
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal … Read more